Terminated PHASE4 INTERVENTIONAL 3-arm NCT00419653

Modulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological Therapy

Modulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological Therapy With Amisulpride, Olanzapine or Haloperidol. A Study With Functional Magnetic Resonance Imaging (fMRI) and Diffusion Tensor Imaging (DTI)

Sponsor: Sanofi

Conditions Schizophrenia

Interventions Amisulpride Haloperidol Olanzapine

Updated 5 times since 2017 Last updated: Sep 15, 2008 Started: Jan 31, 2003 Primary completion: Sep 30, 2007 Completion: Sep 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Recruitment issues

Other terminated trials from Sanofi

See all terminations from Sanofi

Other Schizophrenia trials with similar outcome

Browse all Schizophrenia trials

A PHASE4 clinical study on Schizophrenia, this trial is terminated or withdrawn. The trial is conducted by Sanofi and has accumulated 5 data snapshots since 2003. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE4
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE4
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE4

First recorded

Jan 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sanofi
University of Jena

Data source: University of Jena

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.